⌘K
Loading ticker…
As of 2026-08-21, Incyte Genomics Inc (INCY) has a 3-month relative strength percentile of 88 within the TickerStance CS+ADRC universe (~5,000 tickers). Its Power rating (absolute 1–99) is 59. The current market Stance is 49.9 (Neutral). Sector: Industrials, ranked 5 of 11. Average daily range 3.4%, relative volume 0.73×. TickerStance reports observed regime conditions across the full CS+ADRC universe; band assignment reflects current breadth, momentum, and macro inputs computed at the daily close. Percentile ranks run from 1 (weakest) to 99 (strongest) relative to all universe members on the same date.
INCY is in a stage 2 uptrend, week 8. Currently in a 18-day base; basing ADR 3.3% (broad 3.1%). VCP detected: inconclusive. RS line below base-start high. Distance from 50d / 200d: 10.0% / 23.3%.
Relative strength across horizons plus the leadership score.
Accumulation rating, relative volume, U/D ratio, breakout-day proof.
Daily range, ATR, beta, and the math for a 1-ADR stop.
Diluted EPS, last 8 quarters. Positive EPS uses YoY change.
YoY sales growth, last 8 quarters. Sales must back the earnings story.
TTM operating margin. Expansion = real operating leverage.
YoY common shares outstanding. Down = buyback tailwind. Up > 2% = dilution flag.
Reported figures from SEC filings. No analyst estimates or forward guidance.
INCY is held by 96 ETFs as of May 2026. Top owner: VHT at 0.26% weight, $49M notional. Top 3 carry $122M.
Held by 306 ETFs · $4.0B across latest filings · largest weight 4.91% (PBE).
Top 10 by value, from SEC N-PORT-P filings dated May 2026.
| ETF | Weight | Value | Δ |
|---|---|---|---|
| VHTVanguard Health Care ETF | 0.26% | $49M | — |
| SCHMSchwab U.S. Mid-Cap ETF | 0.30% | $44M | −0.03 pp |
| GSLC | 0.19% | $30M | new |
| SCHXSchwab U.S. Large-Cap ETF | 0.02% | $17M | — |
| FNDA | 0.18% | $16M | −0.09 pp |
| ESGU | 0.09% | $15M | new |
| QGRO | 0.64% | $14M | −0.46 pp |
| VOOG | 0.05% | $12M | — |
| ACWV | 0.34% | $11M | — |
| QQQJ | 0.90% | $10M | −0.09 pp |
Showing 10 of 96 ETF owners.
As filed in N-PORT — quarterly holdings with up to ~60-day publication lag. Not live positioning.
Strong relative strength, but attention is quiet relative to this name’s own recent norm. Academic work links low public attention to better forward returns on average — context to weigh, not a forecast.
Measures how unusual this name’s public attention is against its own 90-day history — a surprise reading, not a ranking of how watched it is versus other stocks. Intel, not a signal.
News
Related searches
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | INCY Jan avg: 2.07% median: 3.66% win: 75% σ: 6.21% n: 4 2022-04-12 → 2026-07-31 | INCY Feb avg: -2.49% median: -0.79% win: 25% σ: 4.82% n: 4 2022-04-12 → 2026-07-31 | INCY Mar avg: -8.29% median: -6.59% win: 0% σ: 6.54% n: 4 2022-04-12 → 2026-07-31 | INCY Apr avg: -1.67% median: 1.22% win: 60% σ: 5.87% n: 5 2022-04-12 → 2026-07-31 | INCY May avg: 0.07% median: 1.54% win: 80% σ: 10.47% n: 5 2022-04-12 → 2026-07-31 | INCY Jun avg: 5.60% median: 4.67% win: 100% σ: 6.81% n: 5 2022-04-12 → 2026-07-31 | INCY Jul avg: 5.47% median: 5.43% win: 100% σ: 3.31% n: 5 2022-04-12 → 2026-07-31 | INCY Aug avg: 1.46% median: 1.09% win: 75% σ: 9.12% n: 4 2022-04-12 → 2026-07-31 (current) | INCY Sep avg: -3.74% median: -2.57% win: 50% σ: 5.27% n: 4 2022-04-12 → 2026-07-31 | INCY Oct avg: 6.82% median: 10.89% win: 75% σ: 9.01% n: 4 2022-04-12 → 2026-07-31 | INCY Nov avg: 5.08% median: 3.96% win: 100% σ: 5.39% n: 4 2022-04-12 → 2026-07-31 | INCY Dec avg: 0.88% median: -2.32% win: 50% σ: 10.39% n: 4 2022-04-12 → 2026-07-31 |